Last reviewed · How we verify
metformin or sulfonylurea
Metformin decreases hepatic glucose production and improves insulin sensitivity, while sulfonylureas stimulate pancreatic beta cells to increase insulin secretion.
Metformin decreases hepatic glucose production and improves insulin sensitivity, while sulfonylureas stimulate pancreatic beta cells to increase insulin secretion. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | metformin or sulfonylurea |
|---|---|
| Sponsor | Dr. Milan Gupta |
| Drug class | Antidiabetic agents (biguanide and sulfonylurea) |
| Target | Metformin: AMP-activated protein kinase (AMPK) pathway; Sulfonylureas: ATP-sensitive potassium channel (KATP) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that reduces gluconeogenesis in the liver and enhances peripheral glucose uptake and utilization, thereby lowering blood glucose without causing hypoglycemia. Sulfonylureas bind to ATP-sensitive potassium channels on beta cells, triggering insulin release to lower blood glucose levels. These are distinct drug classes often used together or separately for type 2 diabetes management.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (metformin)
- Hypoglycemia (sulfonylurea)
- Weight gain (sulfonylurea)
- Lactic acidosis (metformin, rare)
Key clinical trials
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease (PHASE2)
- A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus (PHASE3)
- DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes (PHASE3)
- HbA1c Variability in Type II Diabetes (NA)
- Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metformin or sulfonylurea CI brief — competitive landscape report
- metformin or sulfonylurea updates RSS · CI watch RSS
- Dr. Milan Gupta portfolio CI